GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TDS Pharm Co Ltd (XKRX:464280) » Definitions » Tax Expense

TDS Pharm Co (XKRX:464280) Tax Expense : ₩208 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TDS Pharm Co Tax Expense?

TDS Pharm Co's tax expense for the months ended in Dec. 2024 was ₩-158 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩208 Mil.


TDS Pharm Co Tax Expense Historical Data

The historical data trend for TDS Pharm Co's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TDS Pharm Co Tax Expense Chart

TDS Pharm Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Tax Expense
282.30 355.75 390.36 801.14 493.87

TDS Pharm Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24
Tax Expense Get a 7-Day Free Trial Premium Member Only 313.97 104.55 216.48 149.50 -158.12

TDS Pharm Co Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩208 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TDS Pharm Co  (XKRX:464280) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


TDS Pharm Co Tax Expense Related Terms

Thank you for viewing the detailed overview of TDS Pharm Co's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


TDS Pharm Co Business Description

Traded in Other Exchanges
N/A
Address
253 Pangyo-ro, Pangyo Inno Valley, Building C, Room 403, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.

TDS Pharm Co Headlines

No Headlines